Details

Autor(en) / Beteiligte

• Fu, Yi
• Huang, Yaqian
• Yang, Zhao
• Chen, Yufei
• Zheng, Jingang
• Mao, Chenfeng
• Li, Zhiqing
• Liu, Zhixin
• Yu, Bing
• Li, Tuoyi
• Wang, Meili
• Xu, Chanjuan
• Zhou, Yiwei
• Zhao, Guizhen
• Jia, Yiting
• Guo, Wei
• Jia, Xin
• Zhang, Tao
• Li, Li
• Liu, Ziyi
• Guo, Shengchao
• Ma, Mingliang
• Zhang, Heng
• Liu, Bo
• Du, Junbao
• Wang, Wengong
• Tang, Chaoshu
• Gao, Pei
• Xu, Qingbo
• Wang, Xian
• Liu, Jianfeng
• Sun, Jinpeng
• Kong, Wei

Titel

Cartilage oligomeric matrix protein is an endogenous β-arrestin-2-selective allosteric modulator of AT1 receptor counteracting vascular injury

Ist Teil von

• Cell research, 2021-07, Vol.31 (7), p.773-790

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Compelling evidence has revealed that biased activation of G protein-coupled receptor (GPCR) signaling, including angiotensin II (AngII) receptor type 1 (AT1) signaling, plays pivotal roles in vascular homeostasis and injury, but whether a clinically relevant endogenous biased antagonism of AT1 signaling exists under physiological and pathophysiological conditions has not been clearly elucidated. Here, we show that an extracellular matrix protein, cartilage oligomeric matrix protein (COMP), acts as an endogenous allosteric biased modulator of the AT1 receptor and its deficiency is clinically associated with abdominal aortic aneurysm (AAA) development. COMP directly interacts with the extracellular N-terminus of the AT1 via its EGF domain and inhibits AT1-β-arrestin-2 signaling, but not Gq or Gi signaling, in a selective manner through allosteric regulation of AT1 intracellular conformational states. COMP deficiency results in activation of AT1a-β-arrestin-2 signaling and subsequent exclusive AAA formation in response to AngII infusion. AAAs in COMP or ApoE mice are rescued by AT1a or β-arrestin-2 deficiency, or the application of a peptidomimetic mimicking the AT1-binding motif of COMP. Explorations of the endogenous biased antagonism of AT1 receptor or other GPCRs may reveal novel therapeutic strategies for cardiovascular diseases.